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ABSTRACT 
Objective: The present study was aimed at designing of solid dispersion based pellets of curcumin (Cu) for improving its solubility. 
Methods: Solid dispersion (SD) of Cu was prepared by the melt method using Poloxamer 407 (Pol 407) at a different weight ratio of Cu-Pol 407 (1:2, 1:3, 
1:5, 1:7, 1:10). The solid dispersion was characterised by FTIR, SEM, DSC, XRD and evaluated for saturation solubility in water, drug content and in vitro 
dissolution. The pellets of Cu solid dispersion were prepared by extrusion spheronization technique and optimization was performed by 32full factorial 
design. The pellets were evaluated for size distribution, flow properties, hardness, disintegration and in vitro drug dissolution. 
Results: From the phase solubility analysis, Pol 407 was selected as a Solid dispersion carrier. The formation of Cu-SD by melt method using Pol 
407, was confirmed from FTIR and DSC studies. XRD studies indicated a change of Cu from crystalline to amorphous form. There was a significant 
increase of Cu when formulated as SD compared to plain Cu. The optimization of extrusion spheronization process revealed the significant effect of 
Cu-Pol 407 ratio (p<0.0001) on in vitro dissolution of pellets. Higher Cu dissolution was obtained with Cu-SD pellets compared to plain Cu pellets. 
Conclusion: The present study demonstrated the potential of Cu-SD pellets in improving the solubility of poorly soluble Cu. 
Keywords: Curcumin, Poloxamer, Solid dispersion, Pluronic, Factorial design 
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INTRODUCTION 
Curcumin (Cu) is a phenolic phytoconstituent from the curcuminoid 
group and is obtained from curcuma Longa (family, zingiberaceae), 
traditionally known as turmeric. It is widely used in Indian and 
Chinese traditional medicine [1] and also has been extensively 
studied for its anti-inflammatory [2], anticancer [3], antioxidants [4], 
antibacterial and wound healing activity [5]. The efficacy of Cu in 
hepatoprotection [1], inflammatory bowel disease [4] and lifestyle 
associated diseases is also reported. The clinical potential of Cu is 
limited owing to its low aqueous solubility and poor permeation 
resulting in lower bioavailability and extensive metabolism. As a 
result, Cu is classified into the BCS Class IV compound and its 
therapeutic potential is limited due to its instability in physiological 
conditions[6]. Various formulation approaches have been 
extensively utilized to address the problems of solubility and 
permeability of Cu, out of which, improving solubility and 
dissolution of Cu has been a major area of interest. Solid dispersion 
(SD) of Cu using various water-soluble polymers, 
polyvinylpyrrolidone (PVP) [7], D α-tocopheryl polyethylene glycol 
1000 succinate [8], chremophore and polyethylene glycol (PEG), 
Eudragit E100 [9], carboxymethyl cellulose acetate butyrate [10], 
hydroxypropyl methylcellulose (HPMC) [11], and hydroxypropyl 
methylcellulose acetate succinate [12] and polyethylene glycol-15-
hydroxy stearate (Solutol HS 15) [13] are reported. 
However, the efficiency of Cu to form a stable complex with polymer 
is questionable and a large amount of polymers are needed to obtain 
a desirable effect. With the availability of self-emulsifying and 
surface-active carrier with low melting point, the major focus is now 
shifted to SD formulation using these carriers. One of the interesting 
strategy is the combination of nanotechnology and SD [14]. 
Nanomicellization is achieved with the help of amphiphilic carrier 
that can solubilize the drug in its hydrophobic core and also helps in 
improving the drug stability and solubility. Parika et al. [15] 
Reported self nanomicellizing SD of Cu using soluplus as the carrier. 
However, the use of a high amount of polymer in the self-
nanomicellizing SD may pose a problem in handling and dispensing 
of this formulation. As pellets allow great design flexibility, ease of 
handling, can be easily packed in capsules, free-flowing and 
therefore commercially preferable, the pellet formulation of solid 
dispersion can address this problem.  
In the present study, we have explored the potential of poloxamer 
407 (Pol 407) as a carrier for the solid dispersion (SD) of the Cu. The 
solid dispersion of Cu was loaded on the pellet formulation and 
optimization was performed using design of experiment (DOE). The 
solid-state characterization of SD was done using FTIR, DSC, XRD 
AND SEM and the self micellizing properties were confirmed by 
particle size and zeta potential measurement. Pellet formulation was 
optimized on the basis of size distribution and in vitro dissolution. 
MATERIALS AND METHODS 
Materials 
Curcumin (Phyto Life Science Pvt Ltd Gujrat, India) was received as a 
gift sample. Hydroxypropyl-β-cyclodextrin (HPβCD), PVP K30, PEG 
6000, microcrystalline cellulose, lactose, and crosscarmellose 
Sodium were purchased from Himedia, Mumbai, India. Poloxamer 
407 (Pol 407) (Kolliphor P 407, BASF Mumbai) and Poloxamer 188 
(Pol 188) (Kolliphor P 188, BASF Mumbai) were received as gift 
sample. All the solvents of analytical grade were used in the study. 
Methods 
Phase solubility analysis 
A series of solutions (5, 10, 15, 20, 25, 30 mmol) of different carriers, 
HPβCD, Pol 188, Pol 407, PVP K30, and PEG 6000 were prepared in 0.1 
N HCL. An excess amount of Cu was added to each carrier solution and 
the dispersion was kept to achieve equilibrium at 25 °C for 72 h with 
shaking at 100 rpm in an orbital shaker (Remi, CIS24b2, India). The 
dispersions were filtered through 0.45 µ membrane filter, suitably 
diluted with 0.1 N HCL and the drug concentration in solution was 
analyzed at 429 nm by UV spectrophotometry (Shimadzu, UV 1700, 
Japan). The experiment was performed in triplicate [16, 17].  
Preparation of solid dispersion by melt method 
Solid dispersions of Cu were prepared with different weight ratio, 
1:2, 1:3, 1:5, 1:7 and 1:10 of Cu-Pol 407. The carrier was melted at 
55 °C, and then the Cu was dispersed to molten carrier with constant 
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stirring followed by quick cooling. The obtained dried mass was then 
passed through sieve # 85 and stored in a refrigerator at 4 °C until 
further use [18, 19]. 
Characterization of Cu-SD 
Solid state characterization of Cu-SD and plain Cu were 
characterized by FTIR, DSC and XRD. The morphological 
characterization was done using SEM. 
Scanning electron microscopy 
The surface morphology of Cu-SD formulation was studied using 
field emission scanning electron microscopy (FESEM) (FEI, Nova 
Nano SEM 450, USA). The samples were coated with platinum layer 
of 20 nm to make them electrically conductive and the coated 
samples were then randomly scanned in the FESEM chamber at an 
acceleration voltage of 5.00 KV. The photomicrographs were 
obtained at different magnifications [16]. 
FT-IR study 
IR absorption spectra of Cu, its physical mixture with excipients and 
SD formulation were recorded by potassium bromide dispersion 
technique in which dry samples and potassium bromide were placed 
in the sample holder and infrared spectrum was recorded using 
FTIR Spectrophotometer (Shimadzu, 8400S, Japan) over a range of 
400-4000 cm-1[20].  
Differential scanning calorimetry study 
In order to study the physical state of Cu and Pol 407, DSC 
(PerkinElmer, DSC 4000, USA) study was conducted for Cu, Pol 407 
and Cu-SD. Accurately, 1 mg sample was weighed and placed in a 
sealed aluminum pan, and the sample was heated under nitrogen 
flow (20 ml/min) at a scanning rate of 10 °C per min from 30 to 350 
°C. An empty aluminum pan was used as reference [10].  
X-ray diffraction study 
X-ray diffraction (Rigaku, Miniflex 600, Japan) was performed using 
Cu K 2α rays with a voltage of 40 kV and a current of 15 mA. Samples 
were scanned for 2θ from 20 ° to 80 °. Diffraction patterns for Cu, Pol 
407 and SD of Cu-Pol 407 were obtained [21].  
Characterization of Cu-SD for self-micellizing property 
Particle size measurement 
The particle size of Cu-SD was determined using dynamic light 
scattering (Horiba, SZ 100, Japan). Cu-SD was dissolved in 0.1 N HCL, 
and ultrasonicated for 10 min followed by measurement at fixed 
angle of 90 ° at 25 °C, carried out in triplicate [22].  
Drug content study 
Cu-SD equivalent to 5 mg of Cu was transferred to 50 ml volumetric 
flask, ultrasonicated to 15 min, and diluted to 50 ml with methanol. 
The solution was appropriately diluted by methanol and absorbance 
was noted at maximum wavelength, 419 nm. Drug content was 
determined using the calibration curve in methanol at the same 
wavelength. All the trials were done in triplicate [23, 24].  
Saturation solubility 
The solubility of Cu and Cu-SD was determined in 0.1 N HCL. An 
excess amount of the Cu or Cu-SD was added into 5 ml of 0.1 N HCL 
up to saturation. Then the glass vials were placed into a water bath 
shaker for 72 h at 37 °C±0.5 and 100 rpm. The supernatant solutions 
were then passed through whatman filter paper and analyzed by UV 
spectrophotometry at 419 nm. All solubility measurements were 
performed in triplicate [25]. 
In vitro dissolution study 
In vitro dissolution study was carried out using USP apparatus I 
(basket assembly). Accurately weighed sample equivalent to 20 mg 
of Cu-Pol 407 SD was filled into capsule and placed in a basket of 
dissolution vessel containing 900 ml of 0.1 N HCL as dissolution 
medium, maintained at 37±0.5 °C and 100 rpm. At each time 
interval, 5 ml of the sample was withdrawn and appropriately 
diluted. The equal volume of fresh dissolution medium was 
immediately replaced. The concentration of Cu in the sample was 
analyzed spectrophotometrically at 429 nm. The dissolution 
experiments were conducted in triplicate.  
Preparation of Cu-SD pellets 
The pellets of Cu and Cu-SD were prepared using extrusion and 
spheronization technique. The Cu or Cu-SD was mixed with all other 
excipients, except PVP K30 in a mortar. PVP K30 was dissolved in a 
mixture of IPA and water (2:1 ratio). The PVP solution was added to 
the powder mixture to form a damp mass. The wet mass was then 
passed through sieve number 18 (1000 µm) to obtain cylindrical 
extrudates. The extrudates were placed in a spheronizer (Shakti, SSP 
120, India) fitted with the cross-hatched plate (2 mm) and 
spheronized for 5 min at varying rpm (1100, 1200, 1300 rpm). The 
resulting pellets were dried at 30 °C in a vacuum oven (Bio 
technique, BTI29, India) for 30 min [27]. The composition of pellet 
formulation is shown in table 1. 
 
Table 1: Composition of Cu-SD pellets 
Ingredient Quantity (%w/w) 
 Solid dispersion (Cu-Pol 407) powder 30 
Microcrystalline cellulose 30 
Lactose 30 
Sodium croscarmellose, 5 
Polyvinyl pyrrolidone K30 5 
Isopropyl Alcohol and Distilled water Quantity Sufficient (2:1 ratio) 
 
Table 2: 32 full factorial design for optimization of Cu-SD pellets 
Run Batches (X1) (Cu-Pol 407 ratio)  (X2) (Speed in rpm)  
1 F1 -1 (1:0) -1 (1100) 
2 F2 -1 (1:0) 0 (1200) 
3 F3 -1 (1:0) 1 (1300) 
4 F4 0 (1:3) -1 (1100) 
5 F5 0 (1:3) 0 (1200) 
6 F6 0 (1:3) 1 (1300) 
7 F7 1 (1:7) -1 (1100) 
8 F8 1 (1:7) 0 (1200) 
9 F9 1 (1:7) 1 (1300) 
 
Experimental design 
The optimization of the formulation was performed using 32 full 
factorial design. The design consisted of 2 variables at 3 levels. The 
first independent variable (X1) was Cu-Pol 407 ratio, (1:0, 1:3, 1:7) 
and the other variable (X2) was spheronization speed (1100, 1200, 
1300 rpm). Total of nine formulations were prepared (table 2) and 
the effect on geometric mean diameter (Y1) of pellets, and drug 
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release after 2 h (Y2) was evaluated. The data from 9 trial runs was 
analyzed using Design-Expert software (Stat-Ease, version 9.0, USA). 
The contour plots and 3-D surface response plots were generated in 
order to study the influence of independent variables on responses. 
Characterization of Cu-SD pellet 
Particle size distribution 
The particle size distribution of pellets was carried out by sieve 
analysis, using a set of USP standard sieves. Sieves set of #12, 16, 18, 
22, 24, 30, 36 and 44 were used along with a pellet load of 10 g. The 
sieve set was then mechanically shaken for 10 min. The net weight 
retained on each sieve was determined and these values were used 
for calculation of the particle size distribution [28].  
Scanning electron microscopy 
The surface morphology of Cu-SD pellet formulation was studied 
using field emission scanning electron microscopy (FESEM) (FEI, 
Nova Nano SEM 450, USA). The samples were coated with a 
platinum layer of 20 nm to make them electrically conductive and 
the coated samples were then randomly scanned in the FESEM 
chamber at an acceleration voltage of 5.00 KV. The 
photomicrographs were obtained at different magnifications 
Micromeritic properties 
Micromeritic properties like bulk and tapped density, Carr’s index, 
compressibility index and angle of repose of pellet formulation were 
evaluated as per standard procedure mentioned in USP [28]. 
Hardness 
The measurement of Hardness of pellets was done using a digital 
hardness tester (Veego, India). 
Drug content 
Drug content of pellets was estimated using UV visible 
spectrophotometric method. Pellets were crushed to powder using 
mortar and pestle. Finely crushed sample equivalent to 5 mg of Cu 
was transferred to 50 ml methanol, ultrasonicated to 15 min and 
after appropriate dilution, absorbance was noted at 419 nm. The 
experiment was performed in triplicate and drug content was 
calculated using a previously developed calibration curve in 
methanol [29].  
In vitro dissolution study 
In vitro dissolution study of pellets was performed using the same 
method as mentioned in the characterization of Cu-SD. 
Stability study 
The stability study of pellet formulation was performed at 
conditions as per ICH guidelines for Zone IV. Pellet sample was filled 
in capsules, which was further placed in HDPE container. The 
samples were maintained in the stability chamber with accelerated 
conditions (40 °C±2 °C, 75±5% RH), and intermediate condition (30 
°C±2 °C, 65±5%). The sample were analyzed for appearance, drug 
content and in vitro drug release at 0 and 1 mo time points at both 
the conditions. 
RESULTS AND DISCUSSION 
Phase solubility analysis  
The solubility of Cu in 0.1 N HCL was observed as 0.0018 mmol. With 
increasing carrier concentration over the range of 5 to 30 mmol, the 
Cu solubility was found to be increased in a linear fashion in all the 
carriers as shown in fig. 1. The sudden increase in solubility was 
observed with Pol 407 and PVP K30 as compared to other carriers. 
At 30 mmol concentration of Pol 407, the solubility of Cu was 
observed as 1.659 mmol. Thus, 921.6 fold increase in solubility of Cu 
was observed. Pol 407 is an amphiphilic coblock polymer with a 
large number of polyethylene oxide chains representing hydrophilic 
portion and polypropylene oxide units representing the 
hydrophobic part. At higher concentrations, it forms micelles, thus 
allowing solubilization of hydrophobic drugs in its core resulting in 
improved drug solubility. Considering this, for further study, Pol 407 
was selected as SD carrier. 
 
 
Fig. 1: Phase solubility analysis of Cu in different carriers, *error bars represent standard deviations of three replicates 
 
Formulation and evaluation of Cu-SD 
From the phase solubility plots, considering the high molecular 
weight of Pol 407, Cu solid dispersions were prepared with Cu-
Pol 407 weight ratio of 1:2, 1:3, 1:5, 1:7, 1:10 instead of molar 
ratio. 
Scanning electron microscopy 
Scanning electron micrograph of Cu revealed its crystalline structure 
and Pol 407 appeared as perfectly spherical smooth-surfaced 
particles (fig. 2). The SEM of Cu-SD showed agglomerated particles 
with a rough surface. 
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Fig. 2: Scanning electron micrograph of (a) Cu (b) Pol 407 (c) Cu-SD 
 
 
Fig. 3: FTIR spectra of (a) Cu (b) Pol 407 (c) Cu-SD 
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FT-IR study 
The IR spectra of pure Cu (fig. 3) presented characteristic peaks at 
3471.02-3285.85 cm-1 (O-H stretching), 3156.61 cm-1 (C-H 
stretching), 3004.23 cm-1 (aromatic C–H stretching), 2926.11-
2862.46 cm-1 (asymmetric symmetric stretching of–CH3 group), 
1732.13-1675.23 cm-1 (C=O and C=C stretching in aromatic) and 
733.94 cm-1 (C–H bonding of aromatic group). The IR spectra of pure 
Pol 407 showed peaks at 3153.72 (O–H group stretching), 2924.18-
2868.24 cm-1 (asymmetric and symmetric Stretching of–CH3 and CH 2 
group) and 1140.93 cm-1 (C-O Single bond stretching). 
Cu in its free form has two hydroxyl group with their frequencies at 
3471.02-3285.85 cm-1 and Pol 407 has one hydroxyl group at 
3153.72 cm-1. In the IR spectra of Cu-SD, the decrease in the 
frequencies of hydroxyl group in the range 3510.56-3173.01 cm-1 is 
attributed to hydrogen bonding between Cu and Pol 407. This 
confirms the Cu and Pol 407 interactions during the formation of 
Solid dispersion. 
Differential scanning calorimetry study 
The solid-state changes in Cu-SD were studied by comparing DSC of 
Cu, Pol 407, and Cu-Pol 407 SD (fig. 4). The crystallinity in Cu was 
confirmed by sharp endothermic peak at 178.66 °C. DSC of Pol 407 
demonstrated endotherm at 54.9 °C. The endothermic peak was 
observed at 53.16 °C in Cu-SD. The peak for Cu was not observed. 
This confirmed molecular dispersion of Cu in Pol 407 carrier. 
  
 
Fig. 4: Differential scanning calorimetry of (a) Cu (b) Pol 407 (c) Cu-SD 
 
X-ray diffraction study 
The changes in the crystallinity of Cu in SD formulation were further 
confirmed by XRD. Fig. 5 represents X-Ray diffractogram of Cu, Pol 407, 
and Cu-SD. The sharp characteristic peaks of Cu were observed at 2θ, 
21.12 °, 23.3 °, 25.52 °, 25.56 °, and 28.92 ° in raw Cu sample. This 
confirmed the crystalline nature of Cu. Pol 407 indicated a sharp peak in 
the range, 22.88 ° to 23.78 °. In Cu-SD sample, the sharp peaks of Pol 407 
in the range of 23.12 ° to 23.82 ° were observed but there was a 
complete disappearance of Cu peaks. This indicated a complete change of 
Cu from crystalline to amorphous form. This can be correlated with the 
enhanced solubility and dissolution of Cu-SD as compared to raw Cu. 
 
 
Fig. 5: XRD of (a) Cu (b) Pol 407 (c) Cu-SD 
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Characterization of Cu-SD for self micellizing property 
Pol 407 is a block copolymer with poly (ethylene oxide) (PEO) and 
poly (propylene oxide) (PPO) units. Above critical micelle 
concentration of 2.8x10-6M at 37 °C it forms micelles with PPO unit 
aggregated in the core and PEO units oriented towards the external 
aqueous phase. Micellar solubilization of lipophilic drugs could 
result in an increase in drug solubility. In order to confirm the 
formation of micelles by Pol 407, the particle size distribution was 
conducted after dispersion of SD in water (table 3). 
The solid dispersion formulation showed mean size of micelles in the 
range 721.4 to 1311.7 nm and PDI in range 0.409 to 1.612. Parikh et al. 
[15] reported similar nanomicellizing formulations where the size of 
micelles was obtained as 63.05±5.24 nm with polydispersity index of 
0.09±0.04. In these formulations they used Soluplus and Solutol HS-15 
as polymers. The higher values of the polydispersity index in our 
reported formulations could be the result of excessive Pol 407 present 
in higher Cu-Pol407 ratios. High concentration of Pol 407 may result in 
increase in number of micelles and their size. This could result in 
uneven size distribution of micelles. The drug content of Cu-SD was 
found to be in range 81.56 to 92.02%. 
Saturation solubility 
The result of saturation solubility is depicted in fig. 6. The SD with 
ratio 1:3 demonstrated significant increase in solubility of Cu 
(158.71 mg/ml) as compared to only Cu (0.692 mg/ml) and SD with 
ratio 1:7 demonstrated solubility value of 333.72 mg/ml. Thus, the 
solubility of Cu was significantly increased with increasing ratio of 
Cu-Pol 407. This could be attributed to increase in formation of 
micelles with increase in Cu-Pol 407 ratio. 
  
Table 3: Characterization of Cu-SD for particle size and drug content 
Batch Mean size (d90) (nm) PDI Drug content (%)* 
SD1 721.4 0.409 82.58±0.78 
SD2 878.1 0.759 86.0±0.33 
SD3 1156.6 0.975 88.40±0.20 
SD4 1266.6 1.015 92.27±0.15 
SD5 1311.7 1.612 93.74±0.24 
 *Values are expressed as mean±SD (n=3) 
 
 
Fig. 6: Saturation solubility (mg/ml) (log scale) of Cu and Cu-SD in 0.1 N HCL, *error bars represent standard deviations of three replicates 
 
 
Fig. 7: In vitro dissolution study of Cu-SD formulation, *error bars represent standard deviations of three replicates 
 
In vitro dissolution study of Cu-SD 
Fig. 7 represents in vitro dissolution of Cu solid dispersion 
formulations. Cu-SD demonstrated higher drug release as compared 
to raw Cu. When Cu-Pol 407 ratio was increased from 1:2 to 1:3 
there was no significant increase in drug release. However, with 
increase in ratio to 1:7 and 1:10, the drug release was significantly 
increased. This is in agreement with the reports of Paradkar et al. 
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[30] in which authors reported a solid dispersion system of Cu and 
PVP at different weight ratio. The drug release of solid dispersion 
was significantly higher than pure Cu and ratio 1:7 and 1:10 
demonstrated a significant increase in drug release as compared to 
lower ratios, 1:1, 1:3 and 1:5.  
Considering the results of saturation solubility, particle size and 
in vitro dissolution, the solid dispersion ratios of 1:3 and 1:7 
were selected for the formulation of solid dispersion loaded 
pellets. 
Characterization of Cu-SD pellets 
Pellet formulations of Cu-SD were prepared by extrusion 
spheronization technique in order to overcome the problems of 
agglomeration and poor flowability of solid dispersion due to 
higher poloxamer concentration. Cu-SD was 30% w/w and other 
excipients were 70% w/w in the pellet formulation. Pellet 
formulation by extrusion spheronization takes place through 
various stages, attrition, plastic deformation and agglomeration 
resulting into shape change from cylindrical dumbbells, ellipsoid 
to finally spherical shape pellets. Preliminary trials were 
performed in order to optimize the solvents for the pelletization 
process. Water: IPA (isopropyl alcohol) in 1:4 ratio was used as 
solvent. Increase in water proportion resulted in sticky product 
whereas use of only IPA resulted in friable pellets. From the 
preliminary trials, the spheronization speed was set in the range of 
1100 to 1300 rpm.  
The feasibility of extrusion spheronization process for the formulation 
of pellets containing Cu in free form and in complex form with Pol 407 
was studied using Design of Experiments (DOE). (table 4) depicts the 
effect of independent variables Cu-Pol 407 ratio (X1) and 
spheronization speed (X2) on evaluation parameters. The pellet 
formulation indicated good flow properties and compressibility as 
evident from Hausner ratio and compressibility index. As the 
spheronization speed was increased from 1100 to 1300 rpm, there 
was decrease in the values of angle of repose. For Cu pellets without 
SD (1:0 ratio), the dgeo (geometric mean diameter) of pellet increased 
with increase in spheronization speed (fig. 8). However, with Cu-SD 
pellets, there was no significant change in dgeo with change in 
spheronization speed. During Cu pellet formation, higher speed of 
spheronization resulted in higher attrition producing large amount of 
fines. These fines, during dumbbell phase got deposited in the waist 
region resulting in formation of larger pellets. In Cu-SD pellet, 
presence of Pol 407 in high amount imparted excess cohesion and 
plasticity, thus decreasing the fine production. This resulted in narrow 
size distribution as compared to only Cu pellets. At higher speed, due 
to the deposition of excess fines, the pellet surface was rough resulting 
into increase in the value of angle of repose. The drug content for all 
the pellet formulation was in the range 81.69 to 93.69 %. 
  
Table 4: Effect of independent variables on responses 
Run Batches (Y1) (Geometric mean diameter in µm) (Y2) (Drug release %)* 
1 F1 927.89 19.62±0.32 
2 F2 943.4 19.13±0.07 
3 F3 1066.59 18.55±0.20 
4 F4 954.11 51.45±0.13 
5 F5 955.43 51.94±0.28 
6 F6 934.11 52.15±0.18 
7 F7 916.22 56.3±0.16 
8 F8 905.73 58.29±0.17 
9 F9 964.94 57.5±0.17 
*Values are expressed as mean±SD (n=3) 
 
 
Fig. 8: (a) contour plot (b) Surface response plot showing effect of Cu-Pol 407 ratio and speed on geometric mean diameter 
 
In order to check the relationship between independent variables and 
the responses, multiple liner regression analysis was carried out. The 
significance of the model was checked by ANOVA followed by student 
t-test. Form the ANOVA data, the effect of variables on pellet size was 
observed as insignificant whereas independent variables contributed 
significantly (p<0.050) to drug release after 2 h. 
Equation 1 indicated the effect of independent variables on drug 
release after 2 h (Y2)  
Drug release (%) (Y2) = 52.2+19.13X1+0.14X2+0.57X1X2-13.62X12-
0.52X22--------------1 
The high F value (1740.31) and p value less than 0.05 (p = 0.0001) 
imply the significance of the model. The predicted R2 (0.9961) was in 
reasonable agreement with the adjusted R2 (0.9991). 
Table 5 indicates ANOVA data for response Y2. ANOVA data indicates 
significant effect of Cu-Pol 407 on drug release (p<0.0001). The higher p 
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value (p>0.1) indicated a non-significant effect of spheronization speed 
on drug release. The presence of quadratic tern in the equation indicated 
non-linearity in the response. Equation 1 suggested that X1 had positive 
effect on drug release. The effect was further verified from the response 
surface and the counterplot as shown in (fig. 9). From the surface 
response plot, it was observed that when Cu-Pol 407 ratio was changed 
from 1:0 to 1:3, there was significant increase in the drug dissolution. 
This was due to presence of Pol 407 as solubility enhancer in the solid 
dispersion. Further increase in Cu-Pol 407 ratio to 1:7 increased the Cu 
dissolution, but the change was not very significant. The drug release 
from, SD pellets with Cu-Pol 407 ratio 1:3 was higher as compared to 
their SD formulation. This could be due to presence of hydrophilic 
carriers in pellet formulation. In addition, the uniform size of pellets 
provided a higher surface area for drug release than the agglomerated 
SD powdered formulations. There was no significant difference in the 
dissolution of pellets with different Cu-Pol 407 ratio SD. Change in 
spheronization speed did not significantly affect the dissolution of 
pellets. 
 
Table 5: ANOVA data for response Y2 (%Drug release) 
Analysis of variance table [Partial sum of squares-Type III] 
Source Sum of squares df Mean square F value p-value Prob>F 
Model 2568.81 5 513.76 1740.31 <0.0001* 
X1-Cu: Poloxomer 407 2196.12 1 2196.12 7439.09 <0.0001* 
X2-Spheronization Speed 0.11 1 0.11 0.39 0.5771 
X1X2 1.29 1 1.29 4.36 0.1279 
X12 370.74 1 370.74 1255.82 <0.0001* 
X22 0.55 1 0.55 1.87 0.2652 
Residual 0.89 3 0.30   
Cor Total 2569.70 8    
*indicates significance of the model, Counter plot (fig. 9 A) indicated more than 50% Cu release for ratio of 1:3 and higher. Fig. 10 indicates 
dissolution profile of Cu and Cu-SD pellet. 
 
 
Fig. 9: (a) contour plot (b) Surface response plot showing effect of Cu-Pol 407 ratio and speed on dissolution at 2 h (%) 
 
 
Fig. 10: In vitro dissolution profile of Cu-SD pellet formulation, *error bars represent standard deviations of three replicates 
 
The result of micrometric properties indicated good flow and 
compressibility properties of pellet formulations (table 6). With 
increase in Cu-Pol 407 ratio in pellet formulation to 1:7, flow 
properties were adversely affected. Scanning electron 
micrograph of pellet formulation (fig. 11) confirmed the 
spherical shape of pellets. The surface of pellets was found to be 
rough. This could be due to deposition of fines produced by 
attrition of pellets during spheronization. These results were in 
agreement with our observation during the optimization of the 
pelletization process. 
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Table 6: Micromeritic properties of Cu-SD pellets 
Batch Bulk density Tapped density Hausner’s ratio Carr’s index % Hardness g/cm3 Angle of repose ( °) 
F1 1.05±0.15 1.01±0.17 1.03±0.18 3.8±0.21 1.230±0.41 26.1 ° 
F2 1.06±0.21 1.14±0.25 1.07±0.16 7.01±0.18 1.310±0.35 29.2 ° 
F3 0.87±0.20 1.14±0.29 1.12±020 11.40±0.39 1.400±0.42 33.0 ° 
F4 0.95±0.25 0.98±0.31 1.04±0.22 3.84±0.24 0.800±03.39 25.8 ° 
F5 0.97±0.15 1.01±0.18 1.11±0.19 3.96±0.15 0.830±0.5 27.1 ° 
F6 0.95±0.32 0.98±0.30 1.03±0.24 3.06±0.42 0.850±0.25 31.0 ° 
F7 1.01±0.27 1.12±0.16 1.10±0.32 9.82±0.25 1.00±0.45 30.1 ° 
F8 1.02±0.29 1.06±0.28 1.03±0.37 3.30±0.36 0.988±0.58 27.0 ° 
F9 1.06±0.38 1.23±0.35 1.16±0.27 13.82±0.21 0.970±0.25 32.0 ° 
 *Values are expressed as mean±SD (n=3) 
 
 
Fig. 11: SEM of the surface of Cu-SD pellet at magnification (a) 200 X (b) 500 X (c) 2000 X 
 
Selection of optimized formulation of Cu-SD pellets 
The criteria for the selection of optimized formulations were higher drug 
release and minimum geometric mean diameter. Based on the results of 
pellet size distribution and in vitro dissolution of pellets, F5 (Cu-Pol 407 
ratio 1:3) was selected as an optimized formulation, since at this ratio, 
the higher release of Cu was obtained and further change in ratio did not 
significantly change dissolution profile. Fig. 12 indicates an overlay plot 
and table 7 indicates a comparison of predicted and experimental 
results. The percentage error in predicted and experimental values was 
only 0.14% and 0.48% indicating robustness of pellet formulation. This 
confirms the validation and pellet formulation process. 
 
 
Fig. 12: Overlay plot indicating design space and optimized formulation 
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Table 7: Comparison of predicted values and experimental value of optimized formulation 
Batch Factor Responses Predicted value Experimental value Percentage error 
 
F5 
X1 Cu-Poloxamer ratio (1:3) 
X2 Speed (rpm) (1200) 
Geometric Mean Dimeter (µm) 952.04 955.43 0.14% 
Drug Release after 2 h* (%) 52.19±0.21 51.94±0.28 0.48% 
*Values are expressed as mean±SD (n=3) 
 
Table 8: Stability data of Cu-SD pellet formulation 
 30 °C±2 °C, 65±5% 40 °C±2 °C, 75±5% RH  
0 d 1 mo 0 D 1 mo 
Physical appearance Yellow colour No change Yellow colour No change 
















*Values are expressed as mean±SD (n=3) 
 
Stability study 
The stability of optimized pellet formulation was studied for 1 mo 
and results are evident in table 8. From the data, no major change 
was observed in the appearance, drug content and drug release. This 
indicated the stability of the formulation at the test temperatures. 
CONCLUSION 
Cu-SD pellets were prepared by extrusion spheronization technique 
and the optimization of the formulation was performed by 32 full 
factorial design. Formulation of Cu-SD was confirmed from FTIR and 
DSC studies. The SD was found to increase the Cu solubility and 
dissolution significantly. The optimized Cu-SD pellets were spherical 
with narrow size distribution and indicated significant enhancement 
in Cu dissolution. The formulation was stable and the process was 
robust as confirmed from validation results. Conclusively, Cu-SD 
pellets presents a promising approach indicating an improvement in 
Cu dissolution.  
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